TABLE 2.

Immunogenicity results at the primary time point (day 14 postvaccination)

Dose group≥2-fold increase in antibody concn from baseline (positive response)a≥4-fold increase in antibody concn from baselineaGeometric mean antibody concn (μg/ml) (95% CI)Geometric mean fold rise in antibody concn from baseline (95% CI)
No. of subjects/no. of vaccinated subjects% of subjects95% CINo. of subjects/no. of vaccinated subjects% of subjects95% CI
V710 (5 μg)9/312914, 483/31102, 2651 (39, 66)1.8 (1.4, 2.2)
V710 (30 μg)24/288667, 9615/285434, 72116 (90, 149)4.4 (3.3, 5.7)
V710 (90 μg)27/318770, 9622/317152, 86131 (101, 170)5.5 (4.0, 7.5)
Placebo1/2840, 181/2840, 1823 (16, 34)1.0 (0.9, 1.2)
  • a Shown are the numbers of subjects with the specified increase in antibody concentration and the numbers of vaccinated subjects in the corresponding treatment group.